Lenalidomide Glenmark (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex, altering its substrate specificity. This triggers ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos, leading to anti‑proliferative, pro‑apoptotic, and anti‑angiogenic effects, while also enhancing immune‑mediated tumor cell clearance.

The specific dose and schedule of lenalidomide are determined by the prescribing physician based on the patient’s diagnosis, disease stage, renal function, and concomitant therapies. Dosing recommendations are provided in the product labeling and must be individualized for each patient.

Lenalidomide is classified as pregnancy category X; it is contraindicated in pregnancy because it can cause fetal harm. Women of child‑bearing potential must use effective contraception during treatment and for a defined period after the last dose. Breastfeeding is not recommended as the drug may be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Both lenalidomide and thalidomide belong to the immunomodulatory drug class, but lenalidomide generally shows greater potency, a more favorable safety profile, and lower risk of peripheral neuropathy. Lenalidomide also has distinct anti‑angiogenic and anti‑myeloma activity, making it the preferred option in many treatment protocols for multiple myeloma and del(5q) MDS.

Lenalidomide Glenmark tablets should be stored at temperatures below 25 °C in their original blister pack, protected from moisture and direct light. Do not store in bathrooms or near heat sources. Keep out of reach of children and dispose of unused product according to local regulations.

Lenalidomide is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablets should be swallowed whole with a full glass of water. Patients should follow the dosing schedule provided in the prescription and attend regular monitoring appointments.

The most serious risks include severe neutropenia and thrombocytopenia, which can lead to life‑threatening infections or bleeding, and venous thromboembolism such as deep‑vein thrombosis or pulmonary embolism. Additionally, there is a risk of secondary primary malignancies and severe hypersensitivity reactions. Prompt reporting of symptoms and regular laboratory monitoring are essential.

Lenalidomide is contraindicated in pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, and patients with uncontrolled active infections. Caution is also advised for those with severe renal impairment, uncontrolled cardiovascular disease, or a history of thromboembolic events unless appropriate prophylaxis is in place.